The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis

Table 7 PGE₂ level after adjusted baseline (Mean ± SE) at pre-treatment (day 0), day 14 and day 28

	Time	Firocoxib	PCSO-524	Combination	P-value ^**
Adjusted PGE₂^a (pg/mL)	Day 0	1815.795 ± 0.00	1815.795 ± 0.00	1815.795 ± 0.00^a	0.639
	Day 14	1721.642 ± 88.889	1780.773 ± 85.645	1791.691 ± 82.430^a	0.639
	Day 28	1717.807 ± 94.695	1805.974 ± 91.239	1589.641 ± 87.814^b

^**p-value from repeated measurement ANCOVA for 3 treatments
^{a, b}p-value < 0.05 from multiple comparison within each treatment using Bonferroni test
^aCovariates appearing in the model are evaluated at PGE₂ of every group at week 0 = 1815.795 pg/mL

ISSN: 1746-6148